1 / 18

Realizing value from leading Scandinavian life science research

Realizing value from leading Scandinavian life science research. Accelerator - At a glance. A life science group aiming to create and realize value Majority owner in 6 companies Business model aimed at commercialize life science projects Attractive target areas Large medical needs

upton-suarez
Download Presentation

Realizing value from leading Scandinavian life science research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Realizing value from leading Scandinavian life science research

  2. Accelerator - At a glance • A life science group aiming to create and realize value • Majority owner in 6 companies • Business model aimed at commercialize life science projects • Attractive target areas • Large medical needs • Diagnostics, cancer and orthopedics • Late stage portfolio • 2 medtech products on the way to market • 2 phase II drug development projects in cancer and cardiology • 1 orthopedic drug delivery in clinic Portfolio set to unlock value in 2010

  3. Publicly traded share • Listed on AktieTorget • Market cap ~ 125 MSEK • 1,600 shareholders • Remium market maker

  4. Group companies Leading Scandinavian findings that target large medical needs

  5. Board of Directors Staffan Persson, chair, Senior partner ITP Andreas Bunge, CEO Accelerator Thomas Gur, Consultant Peter Lindell, Senior partner ITP Ingemar Lundström, Prof Linköping University Network Prof Lou Ignarro, UCLA, Nobel Laureate Prof Per Jynge, LITH Steven Lang, ex BD&L Smith & Nephew Jan Sandström, ex VP BD&L AstraZeneca Skilled employees in group 9 Ph D’s employed Dr Oskar Andersson, ex Senior scientist GE Healthcare Ass Prof Jan Olof Karlsson, ex Senior scientist GE Healthcare Dr Marcel Warntjes, ex Scientist Philips Gunnar Strand, ex Sales manager Kodak/Care Stream Adding skills to reap success Academia & Science – Life Science Industry – Entrepreneurs

  6. Financials Conservative use of funds

  7. Risk reward in life science areas • Medtech • Lower risk / lower reward • Shorter development cycle • Drug development • High risk / high reward • Long development cycle • Hybrid projects • Lower development risk but may require extensive market authorization procedures The birth of a drug

  8. Portfolio

  9. Key products and projects * Skruvcoat to follow a different regulatory pathway

  10. SyMRI suite Software for MRI Type Description • Increases efficiency in MRI by • reducing examination time • improving decision support with more data • allows for analysis post scan • Limited throughput in MRI today with examination times averaging 45 min Status & IP CE approved Distribution agreement with Sectra AB, pilots in market Patent pending Ownership 100% SyntheticMR AB Market • 120 million MR scans annually • MR system market: 2 BUS$, • Major players: GE, Philips, Siemens • PACS market: 6 BUS$

  11. ObsQlip Hb detection in dialysis equipment Type Description Hemodialysis Online detection of Hb value in blood for use by patients undergoing dialysis Status & IP Licensed to Fresenius Medical Care for worldwide sales, except US/Canada Final production series made, Market launch Patent approved Ownership & resources 100% OptoQ AB Market 1.7 million patients regularly undergoes dialysis treatment Hemodialysis: 90% of the dialysis market Hemodialysis market: 10.5 BUS$ Fresenius market share in hemodialysis: 38%

  12. PledOx Supportive cancer care drug. Cytoprotective Type Description PLED derivative and LowMEMs (Low Molecular weight Enzyme Mimetic) with SOD mimetic activity. Increases survival and quality of life for patients receiving chemotherapy. Reduces side effects induced by chemotherapy and selectively protects healthy cells, by mimicking the SOD enzyme which protect cell from damage caused by unstable molecules known as free radicals. Status & IP Clinical phase II study in colon cancer ongoing, expected to be finalized in 2010 Partnering 2010/2011 Patent licensed, additional patent applications Ownership 100% PledPharma AB Market Supportive cancer care (in connection with cancer treatment) is estimated to 13 BUS$ Est. market for lead-indication (colon cancer): >1.5 BUS$ Est. potential peak year sales for lead-indication : 400 MUS$

  13. PP-099 Supportive care therapy for acute heart attack treatment Type Increases survival of patients suffering form acuteheart infarcts, by reducing injuries and complications. PLED derivative and LowMEMs (Low Molecular weight Enzyme Mimetic) with SOD mimetic activity. Reduces side effects induced by reperfusion, by mimicking the SOD enzyme which protect cell from damage caused by unstable molecules known as free radicals. Description Status & IP Clinical phase II study in PCI patients approved, expected to start in 2010 Patent licensed and patent applications Ownership 100% PledPharma AB Market 2 million PCI procedures annually, of which 1 million in USA Rate of death after an acute myocardial infarction approaches 10% Incidence of heart-failure after an acute myocardial infarction is 25% Est. market for lead-indication: >1BUS$ Est. potential peak year sales: 300 MUS$

  14. Skruvcoat/Fibmat Type Drug delivery platform, implant improvements Description Local delivery of the established drug Bisphosphonates Lowers the risk of implants loosening by improving the holding power of the bone Lead-indication: Orthopedic trauma screws Status & IP Proof of concept in dental indication Dental clinical program ongoing Development of prototype production, starting clinical program in orthopedics Aiming to partner in 2010 4 patent applications Ownership 100% AddBIO AB Market • Orthopedic and dental implants: 30 billion US$, CAGR 15%. • 100 million screws sold annually • Est. market lead-indication (orthopedic trauma screws) >300 MUS$ • Est. potential peak sales: 60 MUS$

  15. Spago enhanced MRI Contrast agent for MRI using nano particle based molecular imaging Type Description Identifying and locating tumors early and precisely to improve the probability of successful treatment Developing nano particle based contrast agent with a unique in signal intensity and safety profile Status & IP Proof of concept achieved by animal images Prototype product package under development Partnering aimed for in 2010/2011 4 patent applications Ownership 100% Spago Imaging AB • Est. potential peak year sales for lead indication: 360 MUSD (USA) Market

  16. Oedema (not enhanced) Oedema Tumor Tumor Urine Magnevist 16

  17. Expected news flow in 2010 • Sales revenue from SyMRI suite software • First patient included in phase II study of PP-099 in acute PCI • Last patient enrolled in phase II study of PledOx in colon cancer • Results from phase II study of PledOx in colon cancer • Start of Skruvcoat study on hip implants and fixation pins • Commercial agreement for Skruvcoat Portfolio set to unlock value in 2010

  18. Transaction overview 100% of the right issues guaranteed

More Related